The Multifocal Motor Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Multifocal Motor Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Multifocal Motor Neuropathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Multifocal Motor Neuropathy and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Multifocal Motor Neuropathy by five companies/universities/institutes. The top development phase for Multifocal Motor Neuropathy is phase i with three drugs in that stage. The Multifocal Motor Neuropathy pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Multifocal Motor Neuropathy pipeline products market are: Takeda Pharmaceutical, Annexon and Dianthus Therapeutics.
The key targets in the Multifocal Motor Neuropathy pipeline products market include Complement C1s Subcomponent, Complement C1q Subcomponent, and Complement C2.
The key mechanisms of action in the Multifocal Motor Neuropathy pipeline product include Complement C1s Subcomponent Inhibitor with two drugs in Phase I. The Multifocal Motor Neuropathy pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Multifocal Motor Neuropathy pipeline products market including Antibody, and Monoclonal Antibody.
Multifocal Motor Neuropathy overview
Multifocal motor neuropathy (MMN), or multifocal motor neuropathy with conduction block (MMNCB), is a rare acquired motor neuropathy characterized by progressive asymmetric weakness without sensory problems. Symptoms include weakness in the hands and lower arms, cramping, involuntary contractions or twitching, wrist drop, or foot drop. Nerve conduction studies can be used for diagnosis. The main pharmacological treatment option for MMN is intravenous immunoglobulin (IVIg).
For a complete picture of Multifocal Motor Neuropathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
